Furthermore, patients were grouped according to clinicopathological factors, and we found that patients with PSA (≥ 4 ng/ml), Gleason score (9-10), primary treatment outcome (progressive disease (PD)/stable disease (SD)/partial response (PR)), T stage (T3-T4), N stage (N1) and residual tumor (R1-R2) showed higher levels of MAPK8IP2 expression than patients with other features, as shown in Fig. 2A-F. This evidence concerns the gene KLK3 and neoplasm.